Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Suppression of Melanoma-Associated Neoangiogenesis by Bevacizumab

Suppression of Melanoma-Associated Neoangiogenesis by Bevacizumab OBSERVATION Suppression of Melanoma-Associated Neoangiogenesis by Bevacizumab Gesine B. Jaissle, MD; Anja Ulmer, MD; Sigrid Henke-Fahle, MD; Gerhard Fierlbeck, MD; Karl Ulrich Bartz-Schmidt, MD; Peter Szurman, MD Background: Bevacizumab, a potent antibody against the though repetitive administration of local bevacizumab pro- vascular endothelial growth factor (VEGF), has been shown duced the same antiangiogenetic effect, progression of to be effective for treatment of colorectal cancer. Re- the epiretinal tumor plaques could not be stopped with cently, high effectiveness of bevacizumab in combination the local bevacizumab treatment. with paclitaxel has been reported in a single metastatic melanoma case. To our knowledge, we demonstrate for Conclusions: Intraocular administration of the anti- the first time the antiangiogenetic effect of bevacizumab VEGF drug bevacizumab causes immediate and com- in a patient with a vitreous melanoma metastasis. plete regression of melanoma-associated angiogenesis. The rationale for the therapeutic strategy in our patient was Observations: A 68-year-old man with a vitreous mela- an elevated level of VEGF in the vitreous cavity. Be- noma metastasis of the left eye was treated with a revit- cause we could not demonstrate a direct antiprolifera- rectomy combined with intravitreal bevacizumab appli- tive effect of bevacizumab on melanoma metastasis, be- cation because http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Suppression of Melanoma-Associated Neoangiogenesis by Bevacizumab

Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/suppression-of-melanoma-associated-neoangiogenesis-by-bevacizumab-Saeb0ywTFS

References (10)

Publisher
American Medical Association
Copyright
Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/archdermatol.2007.38
pmid
18427047
Publisher site
See Article on Publisher Site

Abstract

OBSERVATION Suppression of Melanoma-Associated Neoangiogenesis by Bevacizumab Gesine B. Jaissle, MD; Anja Ulmer, MD; Sigrid Henke-Fahle, MD; Gerhard Fierlbeck, MD; Karl Ulrich Bartz-Schmidt, MD; Peter Szurman, MD Background: Bevacizumab, a potent antibody against the though repetitive administration of local bevacizumab pro- vascular endothelial growth factor (VEGF), has been shown duced the same antiangiogenetic effect, progression of to be effective for treatment of colorectal cancer. Re- the epiretinal tumor plaques could not be stopped with cently, high effectiveness of bevacizumab in combination the local bevacizumab treatment. with paclitaxel has been reported in a single metastatic melanoma case. To our knowledge, we demonstrate for Conclusions: Intraocular administration of the anti- the first time the antiangiogenetic effect of bevacizumab VEGF drug bevacizumab causes immediate and com- in a patient with a vitreous melanoma metastasis. plete regression of melanoma-associated angiogenesis. The rationale for the therapeutic strategy in our patient was Observations: A 68-year-old man with a vitreous mela- an elevated level of VEGF in the vitreous cavity. Be- noma metastasis of the left eye was treated with a revit- cause we could not demonstrate a direct antiprolifera- rectomy combined with intravitreal bevacizumab appli- tive effect of bevacizumab on melanoma metastasis, be- cation because

Journal

JAMA Dermatology – American Medical Association

Published: Apr 1, 2008

There are no references for this article.